https://www.selleckchem.com/pr....oducts/ziftomenib.ht
019% (1.6%), relevant for future noise-free operation on this qubit-compatible platform.Dissecting tumor heterogeneity is a key to understanding the complex mechanisms underlying drug resistance in cancers. The rich literature of pioneering studies on tumor heterogeneity analysis spurred a recent community-wide benchmark study that compares diverse modeling algorithms. Here we present FastClone, a top-performing algorithm in accuracy in this benchmark. FastClone improves over existing methods by allowing the deconvolution of subclone
Like
Comment
Share
